Frost & Sullivan has awarded Metabolomic Technologies its 2014 North American Frost & Sullivan Award for Technology Innovation Leadership in recognition of the company's metabolomic screening test PolypDx.
PolypDx uses a proprietary technology platform to detect adenomatous polyps. The test uses metabolite biomarkers to detect polyps before they become malignant.
"PolypDx can be integrated into the diagnostic process for colon cancer and lowers the overall costs incurred by a patient who would otherwise have to undergo a colonoscopy just to assess polyp presence," said Frost & Sullivan Research Analyst Madhumitha Rangesa.